Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques

J Am Chem Soc. 2013 Oct 30;135(43):16120-32. doi: 10.1021/ja4057807. Epub 2013 Oct 16.

Abstract

One of the pathological hallmarks of Alzheimer's disease is the presence of amyloid-β plaques in the brain and the major constituent of these plaques is aggregated amyloid-β peptide. New thiosemicarbazone-pyridylhydrazine based ligands that incorporate functional groups designed to bind amyloid-β plaques have been synthesized. The new ligands form stable four coordinate complexes with a positron-emitting radioactive isotope of copper, (64)Cu. Two of the new Cu(II) complexes include a functionalized styrylpyridine group and these complexes bind to amyloid-β plaques in samples of post-mortem human brain tissue. Strategies to increase brain uptake by functional group manipulation have led to a (64)Cu complex that effectively crosses the blood-brain barrier in wild-type mice. The new complexes described in this manuscript provide insight into strategies to deliver metal complexes to amyloid-β plaques.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / diagnostic imaging*
  • Amyloid beta-Peptides / chemistry*
  • Animals
  • Chromatography, High Pressure Liquid
  • Copper / chemistry*
  • Copper Radioisotopes / chemistry
  • Crystallography, X-Ray
  • Dogs
  • Electrochemistry
  • Humans
  • Ligands
  • Mice
  • Models, Molecular
  • Molecular Conformation
  • Plaque, Amyloid / diagnostic imaging*
  • Positron-Emission Tomography
  • Radiopharmaceuticals / chemistry*
  • Radiopharmaceuticals / pharmacokinetics
  • Spectrometry, Mass, Electrospray Ionization
  • Spectrophotometry, Ultraviolet
  • Tissue Distribution

Substances

  • Amyloid beta-Peptides
  • Copper Radioisotopes
  • Ligands
  • Radiopharmaceuticals
  • Copper